Toll Free: 1-888-928-9744

Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 1065 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H1 2016', provides an overview of the Non-Hodgkin Lymphoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
- The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 8 Non-Hodgkin Lymphoma Overview 9 Therapeutics Development 10 Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 12 Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 22 Non-Hodgkin Lymphoma - Pipeline Products Glance 24 Non-Hodgkin Lymphoma - Products under Development by Companies 28 Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 46 Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 48 Non-Hodgkin Lymphoma - Therapeutics Assessment 172 Drug Profiles 198 Non-Hodgkin Lymphoma - Recent Pipeline Updates 644 Non-Hodgkin Lymphoma - Dormant Projects 1009 Non-Hodgkin Lymphoma - Discontinued Products 1026 Non-Hodgkin Lymphoma - Product Development Milestones 1031 Appendix 1039
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016 35 Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016 36 Number of Products under Development by Companies, H1 2016 37 Number of Products under Development by Companies, H1 2016 (Contd..1) 38 Number of Products under Development by Companies, H1 2016 (Contd..2) 39 Number of Products under Development by Companies, H1 2016 (Contd..3) 40 Number of Products under Development by Companies, H1 2016 (Contd..4) 41 Number of Products under Development by Companies, H1 2016 (Contd..5) 42 Number of Products under Development by Companies, H1 2016 (Contd..6) 43 Number of Products under Development by Companies, H1 2016 (Contd..7) 44 Number of Products under Development by Companies, H1 2016 (Contd..8) 45 Number of Products under Development by Companies, H1 2016 (Contd..9) 46 Number of Products under Investigation by Universities/Institutes, H1 2016 48 Comparative Analysis by Late Stage Development, H1 2016 49 Comparative Analysis by Clinical Stage Development, H1 2016 50 Comparative Analysis by Early Stage Development, H1 2016 51 Comparative Analysis by Unknown Stage Development, H1 2016 52 Products under Development by Companies, H1 2016 53 Products under Development by Companies, H1 2016 (Contd..1) 54 Products under Development by Companies, H1 2016 (Contd..2) 55 Products under Development by Companies, H1 2016 (Contd..3) 56 Products under Development by Companies, H1 2016 (Contd..4) 57 Products under Development by Companies, H1 2016 (Contd..5) 58 Products under Development by Companies, H1 2016 (Contd..6) 59 Products under Development by Companies, H1 2016 (Contd..7) 60 Products under Development by Companies, H1 2016 (Contd..8) 61 Products under Development by Companies, H1 2016 (Contd..9) 62 Products under Development by Companies, H1 2016 (Contd..10) 63 Products under Development by Companies, H1 2016 (Contd..11) 64 Products under Development by Companies, H1 2016 (Contd..12) 65 Products under Development by Companies, H1 2016 (Contd..13) 66 Products under Development by Companies, H1 2016 (Contd..14) 67 Products under Development by Companies, H1 2016 (Contd..15) 68 Products under Development by Companies, H1 2016 (Contd..16) 69 Products under Development by Companies, H1 2016 (Contd..17) 70 Products under Investigation by Universities/Institutes, H1 2016 71 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 72 Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016 73 Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016 74 Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016 75 Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 76 Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H1 2016 77 Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 78 Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016 79 Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH , H1 2016 80 Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2016 81 Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016 82 Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016 83 Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2016 84 Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016 85 Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 86 Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics, Inc., H1 2016 87 Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 88 Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 89 Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics, Inc., H1 2016 90 Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016 91 Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 92 Non-Hodgkin Lymphoma - Pipeline by BioAtla, LLC, H1 2016 93 Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2016 94 Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H1 2016 95 Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2016 96 Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd., H1 2016 97 Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 98 Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical, Inc., H1 2016 99 Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 100 Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016 101 Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016 102 Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016 103 Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 104 Non-Hodgkin Lymphoma - Pipeline by Cellectis S.A., H1 2016 105 Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016 106 Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 107 Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp. z o.o., H1 2016 108 Non-Hodgkin Lymphoma - Pipeline by CerRx, Inc., H1 2016 109 Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016 110 Non-Hodgkin Lymphoma - Pipeline by Clonz Biotech Private Limited, H1 2016 111 Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016 112 Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 113 Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 114 Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 115 Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 116 Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 117 Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016 118 Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 119 Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 120 Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals, Inc., H1 2016 121 Non-Hodgkin Lymphoma - Pipeline by Galderma S.A., H1 2016 122 Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016 123 Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016 124 Non-Hodgkin Lymphoma - Pipeline by Genzyme Corporation, H1 2016 125 Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 126 Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 127 Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2016 128 Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016 129 Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016 130 Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 131 Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 132 Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016 133 Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 134 Non-Hodgkin Lymphoma - Pipeline by Innate Pharma S.A., H1 2016 135 Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H1 2016 136 Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016 137 Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 138 Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H1 2016 139 Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 140 Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co., Ltd., H1 2016 141 Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 142 Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016 143 Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 144 Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016 145 Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 146 Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics, Inc., H1 2016 147 Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 148 Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016 149 Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H1 2016 150 Non-Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016 151 Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016 152 Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 153 Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 154 Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016 155 Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Incorporated, H1 2016 156 Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 157 Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2016 158 Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2016 159 Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H1 2016 160 Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016 161 Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H1 2016 162 Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 163 Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 164 Non-Hodgkin Lymphoma - Pipeline by Polyphor Ltd., H1 2016 165 Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 166 Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 167 Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 168 Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H1 2016 169 Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016 170 Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2016 171 Non-Hodgkin Lymphoma - Pipeline by SciTech Development, LLC , H1 2016 172 Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 173 Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 174 Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 175 Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 176 Non-Hodgkin Lymphoma - Pipeline by SialoTec GmbH , H1 2016 177 Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016 178 Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma K.K., H1 2016 179 Non-Hodgkin Lymphoma - Pipeline by Soligenix, Inc., H1 2016 180 Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016 181 Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 182 Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016 183 Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H1 2016 184 Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 185 Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 186 Non-Hodgkin Lymphoma - Pipeline by Targazyme, Inc., H1 2016 187 Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2016 188 Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 189 Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 190 Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016 191 Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H1 2016 192 Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016 193 Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016 194 Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 195 Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H1 2016 196 Assessment by Monotherapy Products, H1 2016 197 Assessment by Combination Products, H1 2016 198 Number of Products by Stage and Target, H1 2016 200 Number of Products by Stage and Mechanism of Action, H1 2016 211 Number of Products by Stage and Route of Administration, H1 2016 220 Number of Products by Stage and Molecule Type, H1 2016 222 Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 669 Non-Hodgkin Lymphoma - Dormant Projects, H1 2016 1034 Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016 1035 Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016 1036 Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016 1037 Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016 1038 Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016 1039 Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016 1040 Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016 1041 Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016 1042 Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016 1043 Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016 1044 Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016 1045 Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016 1046 Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H1 2016 1047 Non-Hodgkin Lymphoma - Dormant Projects (Contd..14), H1 2016 1048 Non-Hodgkin Lymphoma - Dormant Projects (Contd..15), H1 2016 1049 Non-Hodgkin Lymphoma - Dormant Projects (Contd..16), H1 2016 1050 Non-Hodgkin Lymphoma - Discontinued Products, H1 2016 1051 Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016 1052 Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016 1053 Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016 1054 Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016 1055


List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016 35 Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016 36 Number of Products under Development by Companies, H1 2016 37 Number of Products under Investigation by Universities/Institutes, H1 2016 47 Comparative Analysis by Late Stage Development, H1 2016 49 Comparative Analysis by Clinical Stage Development, H1 2016 50 Comparative Analysis by Early Stage Products, H1 2016 51 Assessment by Monotherapy Products, H1 2016 197 Assessment by Combination Products, H1 2016 198 Number of Products by Top 10 Targets, H1 2016 199 Number of Products by Stage and Top 10 Targets, H1 2016 199 Number of Products by Top 10 Mechanism of Actions, H1 2016 210 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 210 Number of Products by Top 10 Routes of Administration, H1 2016 219 Number of Products by Stage and Routes of Administration, H1 2016 219 Number of Products by Top 10 Molecule Types, H1 2016 221 Number of Products by Stage and Top 10 Molecule Types, H1 2016 221

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify